This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2014 by Sidney Kimmel Comprehensive Cancer Center.
Recruitment status was:  Active, not recruiting
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center Identifier:
First received: August 7, 2008
Last updated: October 1, 2014
Last verified: October 2014

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Infusing doxorubicin beads into the liver, and blocking blood flow to the tumor, may keep doxorubicin near the tumor and kill more tumor cells.

PURPOSE: This clinical trial is studying the side effects of doxorubicin beads and to see how well they work in treating patients with unresectable liver metastases from neuroendocrine tumors.

Condition Intervention
Gastrointestinal Carcinoid Tumor Islet Cell Tumor Metastatic Cancer Drug: PVA microporous hydrospheres/doxorubicin hydrochloride

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Patients With Hepatic Neuroendocrine Metastases Using Drug-Eluting Bead Embolization

Resource links provided by NLM:

Further study details as provided by Sidney Kimmel Comprehensive Cancer Center:

Primary Outcome Measures:
  • Tumor response (efficacy) [ Time Frame: Time to progression ]
  • Safety [ Time Frame: 30 days post study exit ]

Secondary Outcome Measures:
  • Survival [ Time Frame: overall survival ]
  • Biochemical response [ Time Frame: Time to progression ]
  • Symptomatic response [ Time Frame: Time to progression ]

Estimated Enrollment: 30
Study Start Date: February 2009
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: single arm Drug: PVA microporous hydrospheres/doxorubicin hydrochloride

Detailed Description:



  • To gather preliminary data and determine the feasibility of a randomized study of patients with unresectable hepatic neuroendocrine metastases using PVA microporous hydrospheres/doxorubicin hydrochloride.

OUTLINE: A catheter is placed into the right or left hepatic artery. Patients with unifocal tumors will have the catheter or microcatheter placed more selectively into the 2nd or 3rd order branch off the right or left hepatic artery in closer proximity to the tumor. PVA microporous hydrospheres/doxorubicin hydrochloride mixture is injected into the delivery area.

Patients with less than 75% necrosis at 1 month undergo a second (and possibly a third a month later) chemoembolization.

After completion of study therapy, patients are followed at 1 month, every 2 months for 1 year, and then every 3 months for 1 year.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


Inclusion criteria:

  • Diagnosis of hepatic neuroendocrine metastases not suitable for radical therapies (e.g., resection or liver transplantation)

    • Histologically proven neuroendocrine tumor
    • Tumors are hypervascular based on visual estimation by investigator
  • Predominant to the liver disease, but extrahepatic disease is not an exclusion

    • No predominant extrahepatic liver disease
    • No significant life-threatening extrahepatic disease, in the judgment of the physician
  • Recent-interval progression of hepatic liver metastases
  • No diffuse hepatic neuroendocrine metastases defined as massive ill-defined tumor involvement measuring > 90% tumor burden

Exclusion criteria:

  • Clinically evident ascites (a radiographic finding of trace ascites on imaging is acceptable)
  • Complete occlusion of the entire portal venous system
  • Evidence of cirrhosis or portal hypertension
  • Vascular resistance peripheral to the feeding arteries precluding passage of PVA microporous hydrospheres/doxorubicin hydrochloride


Inclusion criteria:

  • ECOG performance status 0-2
  • Must have preserved liver function (Child-Pugh class A-B) without significant liver decompensation

    • No advanced liver disease (e.g., Child-Pugh C class or active gastrointestinal bleeding, encephalopathy, or ascites [trace ascites is acceptable]), meeting the following criteria:

      • Bilirubin > 3 mg/dL
      • AST, ALT, and alkaline phosphatase > 5 times upper limit of normal
      • Serum creatinine > 2.0 mg/dL
      • Albumin ≤ 2.0 g/dL
  • No vascular anatomy or blood that precludes catheter placement or emboli injection
  • No presence of arteries supplying the lesion not large enough to accept PVA microporous hydrospheres/doxorubicin hydrochloride
  • No collateral vessel pathways potentially endangering normal territories during embolization
  • No feeding arteries smaller than distal branches from which they emerge
  • Not pregnant

Exclusion criteria:

  • See Disease Characteristics
  • Another active primary tumor
  • Any contraindication for hepatic embolization procedures, including any of the following:

    • Porto-systemic shunt
    • Hepatofugal blood flow
    • Impaired clotting tests (i.e., platelet count < 50,000/mm³, INR ≥ 1.8, or PTT ≥ 39 seconds)
    • Renal failure
    • Severe peripheral vascular disease precluding catheterization
  • Any contraindication for doxorubicin hydrochloride administration (i.e., serum bilirubin > 5 mg/dL or leukocyte count < 1,500 cells/mm³)
  • Allergy to contrast media
  • Intolerant to occlusion procedures
  • Presence of end arteries leading directly to cranial nerves
  • Presence or likely onset of hemorrhage
  • Presence of severe atheromatous disease


Exclusion criteria:

  • Prior anticancer therapy for hepatic neuroendocrine metastases, except previous surgical therapy
  • Any continuing complication or prior cancer therapy that has not improved or resolved prior to 21 days before start of treatment, if the investigator determines that the continuing complication will compromise the safety of the patient after treatment with PVA microporous hydrospheres/doxorubicin hydrochloride
  • Presence of patent extra-to-intracranial anastomoses or shunts
  • Use of PVA microporous hydrospheres/doxorubicin hydrochloride in the following applications:

    • Embolization of large-diameter arteriovenous shunts
    • Pulmonary arterial vasculature
    • Any vasculature where the use of PVA microporous hydrospheres/doxorubicin hydrochloride could pass directly into the internal carotid artery or the above-listed vessels
  • Concurrent enrollment in another clinical study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00730483

United States, Maryland
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States, 21231-2410
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Jeffrey F. Geschwind, MD Sidney Kimmel Comprehensive Cancer Center
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Sidney Kimmel Comprehensive Cancer Center Identifier: NCT00730483     History of Changes
Other Study ID Numbers: J0739 CDR0000601054
Study First Received: August 7, 2008
Last Updated: October 1, 2014

Keywords provided by Sidney Kimmel Comprehensive Cancer Center:
liver metastases
metastatic gastrointestinal carcinoid tumor
regional gastrointestinal carcinoid tumor
islet cell carcinoma
pancreatic polypeptide tumor

Additional relevant MeSH terms:
Neoplasm Metastasis
Carcinoid Tumor
Neuroendocrine Tumors
Malignant Carcinoid Syndrome
Gastrointestinal Neoplasms
Adenoma, Islet Cell
Neoplastic Processes
Pathologic Processes
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Pancreatic Neoplasms
Endocrine Gland Neoplasms
Pancreatic Diseases
Endocrine System Diseases
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors processed this record on August 22, 2017